Breaking News
The U.S. Food and Drug Administration has approved KERENDIA (finerenone) for adults with chronic kidney disease associated with type 1 diabetes.
The Centers for Disease Control and Prevention is merging its Influenza Division with the Coronavirus and Other Respiratory Diseases Division to create the Influenza and Respiratory Viruses Division.
The Centers for Disease Control and Prevention has issues its recommendations for use of the seasonal 2026-2027 influenza (flu) vaccines.
The U.S. Food and Drug Administration has approved Takeda’s Orzeyful (oveporexton) tablets to treat narcolepsy type 1 in adults.
A new study has found infants are far more vulnerable than older children to severe illness from viruses such as influenza, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and SARS-CoV-2.
The U.S. Food and Drug Administration has approved mFLUSIVA (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older.
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
BSTQ Podcast
Healthcare Marketplace News & Insights
The BioSupply Trends Quarterly (BSTQ) Podcast brings together healthcare professionals, researchers, innovators and advocates to explore the scientific, clinical and operational trends shaping the future of biotherapeutics, healthcare delivery and public health.
